A Phase 2 Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of AL002 in Participants with Early Alzheimer's Disease
Purpose
Category
IRB Number
20220237HU
NCT Number
-
Sponsor
-
Study Contact
Principal Investigator
Alicia Parker
Floyd Jones
210-450-3158
jonesfa@uthscsa.edu
Eligibility
Eligible Ages
Eligible Genders
Accepts Healthy Volunteers
No
Inclusion Criteria
Exclusion Criteria
Study Design
Arm Groups